International Association for the Study of Lung Cancer Sep 9 2025 New research presented identifies interferon-induced transmembrane protein 3 (IFITM3) as a critical regulator of immunotherapy sensitivity in small cell lung cancer (SCLC), offering a promising new avenue for overcoming resistance to PD-1/PD-L1 checkpoint blockade. The research was presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC). SCLC tumors are typically